CV:XRTX XORTX Therapeutics Inc.

XORTX Therapeutics, Inc. engages in developing innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol XRTXF.

This company has cross-listed shares that trade in the U.S. as the symbol XRTXF.

1.15 CAD
As of 11/30/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   23,511,356 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy